Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC.
In conclusion, upfront use of next-generation TKIs in patients with oncogene-driven NSCLC with symptomatic CNS metastases is associated with reasonable intracranial activity and represents a valuable treatment option.
PMID: 32963526 [PubMed]
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Clinical Trials | Headache | Lung Cancer | Migraine | Neurology | Non-Small Cell Lung Cancer | Radiography | Study